View Older Stories View More Recent Stories

Aug 8, 2022 05:49AM AstraZeneca (AZN) Announces ENHERTU Approved in US for Patients with HER2-low Metastatic Breast Cancer
Aug 5, 2022 08:06PM ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer
Aug 5, 2022 02:20PM AstraZeneca (AZN) announces CALQUENCE tablet formulation approved in the US across current indications
Aug 5, 2022 02:20PM CALQUENCE® (acalabrutinib) tablet formulation approved in the US across current indications
Jul 25, 2022 07:00AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low metastatic breast cancer
Jul 1, 2022 09:01AM AstraZeneca (AZN) Reports Data for IMFINZI Combinations in Patients With Liver and Biliary Tract Cancers
Jul 1, 2022 09:00AM AstraZeneca Shares Data at EASL and ESMO World GI for IMFINZI® (durvalumab) Combinations in Patients With Liver and Biliary Tract Cancers
Jun 30, 2022 07:00AM IMFINZI® (durvalumab) Plus Chemotherapy Significantly Improved Pathologic Complete Response in AEGEAN Phase III Trial in Resectable Non-Small Cell Lung Cancer
Jun 23, 2022 08:36AM AstraZeneca (AZN) Reports ALXN1840 Shows Rapid and Sustained Improvement in Copper Mobilization From Tissues
Jun 23, 2022 08:35AM ALXN1840 Shows Rapid and Sustained Improvement in Copper Mobilization From Tissues, Potentially Closing Treatment Gaps for Wilson Disease Community
Jun 21, 2022 07:05AM PROpel Phase III Trial Positive Results of LYNPARZA® (olaparib) Plus Abiraterone in 1st-line Metastatic Castration-resistant Prostate Cancer Published in New England Journal of Medicine Evidence
Jun 21, 2022 07:00AM Eplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the NEURO-TTRansform Phase III Trial for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN)
Jun 5, 2022 08:10AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2-Low Metastatic Breast Cancer with HR-Positive and HR-Negative
Jun 4, 2022 10:00AM CALQUENCE Plus Obinutuzumab Demonstrated Sustained Survival Benefit in 1st-line Chronic Lymphocytic Leukemia with 90% of Patients Surviving Five Years in ELEVATE-TN Trial
May 27, 2022 09:00AM First Patients Dosed in IRIS Phase III Trial Evaluating Anifrolumab in Lupus Nephritis
May 23, 2022 07:00AM AstraZeneca aims to transform cancer care with practice-changing data at ASCO 2022
May 15, 2022 01:24PM PT027, a Novel Fixed-Dose Combination of Albuterol and Budesonide, Used as an As-Needed Rescue Medicine, Significantly Reduced the Risk of a Severe Exacerbation Compared to Albuterol by 27% in Patient
May 5, 2022 07:05AM FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction
May 5, 2022 07:00AM ULTOMIRIS® (ravulizumab-cwvz) Met Primary Endpoint in CHAMPION-NMOSD Phase III Trial in Adults with Neuromyelitis Optica Spectrum Disorder
May 5, 2022 07:00AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
May 4, 2022 08:00AM Imfinzi Plus Chemotherapy Granted Priority Review in the US for Patients With Locally Advanced or Metastatic Biliary Tract Cancer Based on TOPAZ-1 Phase III Trial
May 3, 2022 07:00AM Blueprint Medicines Reports First Quarter 2022 Results
Apr 28, 2022 07:00AM ULTOMIRIS® (ravulizumab-cwvz) Approved in the US for Adults with Generalized Myasthenia Gravis
Apr 27, 2022 07:00AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US for patients with HER2-low metastatic breast cancer
Apr 25, 2022 08:00AM Tremelimumab accepted under Priority Review in the US for patients with unresectable liver cancer in combination with Imfinzi
Apr 20, 2022 06:12PM EVUSHELD™  significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations
Apr 19, 2022 07:00AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
Apr 8, 2022 01:00PM Blueprint Medicines Announces BLU-945 Proof-of-Concept Data Supporting Initiation of Comprehensive Combination Development Strategy in EGFR-mutant Non-Small Cell Lung Cancer
Apr 6, 2022 07:00AM ULTOMIRIS® (ravulizumab-cwvz) demonstrated sustained improvements in functional activities and quality of life in adults with generalized myasthenia gravis through 60 weeks
Apr 4, 2022 01:54PM PGA Champion Jason Day Launches Getting Out of the Rough Video Series With AstraZeneca to Support Lung Cancer Biomarker Testing Awareness
Mar 24, 2022 07:00AM AstraZeneca Announces New Partnership with The National Fish and Wildlife Foundation to Plant One Million Trees
Mar 21, 2022 07:00AM EVUSHELD™ long-acting antibody combination retains neutralizing activity against Omicron variants including BA.2 in new independent studies
Mar 16, 2022 01:32PM UPDATE: AstraZeneca (AZN), Merck (MRK) Said LYNPARZA Reduced Risk of Death by 32% in Breast Cancer Trial
Mar 16, 2022 01:30PM LYNPARZA® (olaparib) reduced risk of death by 32% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer
Mar 11, 2022 07:53PM LYNPARZA® (olaparib) approved in the US as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer
Feb 21, 2022 11:15AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) Significantly Improved Both Progression-Free and Overall Survival in DESTINY-Breast04 Trial in Patients with HER2-Low Metastatic Breast Cancer
Feb 14, 2022 05:04PM AstraZeneca (AZN) and Merck (MRK) Announce LYNPARZA plus Abiraterone Reduced Risk of Disease Progression by 34% vs. Standard-of-Care in 1st-Line Metastatic Castration-Resistant Prostate Cancer
Feb 14, 2022 05:00PM LYNPARZA® (olaparib) plus Abiraterone Reduced Risk of Disease Progression by 34% vs. Standard-of-Care in 1st-Line Metastatic Castration-Resistant Prostate Cancer
Feb 14, 2022 05:56AM Glenmark inks agreement with AstraZeneca to commercialize its product Pulmicort Respules® in Colombia
Feb 10, 2022 05:02PM AstraZeneca (AZN) to Join Nasdaq-100 Index
Feb 10, 2022 05:00PM AstraZeneca PLC – ADR to Join the NASDAQ-100 Index Beginning February 22, 2022
Feb 10, 2022 05:00PM AstraZeneca PLC – ADR to Join the NASDAQ-100 Index Beginning February 22, 2022
Jan 24, 2022 07:10AM AstraZeneca (AZN) announces Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis
Jan 24, 2022 07:10AM Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis
Jan 18, 2022 05:50PM IMFINZI® (durvalumab) Plus Tremelimumab Demonstrated Unprecedented Survival in 1st-line Unresectable Liver Cancer With 31% of Patients Alive at Three Years
Jan 18, 2022 05:20PM IMFINZI® (durvalumab) Plus Chemotherapy Reduced Risk of Death by 20% in 1st-Line Advanced Biliary Tract Cancer
Jan 17, 2022 07:00AM Enhertu Granted Priority Review in the US for Patients With HER2-Positive Metastatic Breast Cancer Treated With a Prior Anti-HER2-Based Regimen
Jan 17, 2022 07:00AM CORRECTING and REPLACING ENHERTU® granted Priority Review in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
Jan 13, 2022 07:07AM AstraZeneca (AZN) Aims to Redefine Liver, Biliary Tract and Prostate Cancer Treatment With Practice-Changing IMFINZI and LYNPARZA Data at ASCO GI and GU
Jan 13, 2022 07:05AM AstraZeneca Aims to Redefine Liver, Biliary Tract and Prostate Cancer Treatment With Practice-Changing IMFINZI® (durvalumab) and LYNPARZA® (olaparib) Data at ASCO GI and GU
View More Recent Stories View Older Stories